288 related articles for article (PubMed ID: 33290397)
1. Targeting TMPRSS2 and Cathepsin B/L together may be synergistic against SARS-CoV-2 infection.
Padmanabhan P; Desikan R; Dixit NM
PLoS Comput Biol; 2020 Dec; 16(12):e1008461. PubMed ID: 33290397
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous Inhibition of SARS-CoV-2 Entry Pathways by Cyclosporine.
Prasad K; Ahamad S; Kanipakam H; Gupta D; Kumar V
ACS Chem Neurosci; 2021 Mar; 12(5):930-944. PubMed ID: 33606519
[TBL] [Abstract][Full Text] [Related]
3. Modelling how increased Cathepsin B/L and decreased TMPRSS2 usage for cell entry by the SARS-CoV-2 Omicron variant may affect the efficacy and synergy of TMPRSS2 and Cathepsin B/L inhibitors.
Padmanabhan P; Dixit NM
J Theor Biol; 2023 Sep; 572():111568. PubMed ID: 37393986
[TBL] [Abstract][Full Text] [Related]
4. Genomics-guided identification of potential modulators of SARS-CoV-2 entry proteases, TMPRSS2 and Cathepsins B/L.
Prasad K; AlOmar SY; Almuqri EA; Rudayni HA; Kumar V
PLoS One; 2021; 16(8):e0256141. PubMed ID: 34407143
[TBL] [Abstract][Full Text] [Related]
5. Synergistic Block of SARS-CoV-2 Infection by Combined Drug Inhibition of the Host Entry Factors PIKfyve Kinase and TMPRSS2 Protease.
Kreutzberger AJB; Sanyal A; Ojha R; Pyle JD; Vapalahti O; Balistreri G; Kirchhausen T
J Virol; 2021 Oct; 95(21):e0097521. PubMed ID: 34406858
[TBL] [Abstract][Full Text] [Related]
6. Targeting the viral-entry facilitators of SARS-CoV-2 as a therapeutic strategy in COVID-19.
Muralidar S; Gopal G; Visaga Ambi S
J Med Virol; 2021 Sep; 93(9):5260-5276. PubMed ID: 33851732
[TBL] [Abstract][Full Text] [Related]
7. In Silico Identification of Potential Natural Product Inhibitors of Human Proteases Key to SARS-CoV-2 Infection.
Vivek-Ananth RP; Rana A; Rajan N; Biswal HS; Samal A
Molecules; 2020 Aug; 25(17):. PubMed ID: 32842606
[TBL] [Abstract][Full Text] [Related]
8. TMPRSS2 expression dictates the entry route used by SARS-CoV-2 to infect host cells.
Koch J; Uckeley ZM; Doldan P; Stanifer M; Boulant S; Lozach PY
EMBO J; 2021 Aug; 40(16):e107821. PubMed ID: 34159616
[TBL] [Abstract][Full Text] [Related]
9. Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2.
Ou T; Mou H; Zhang L; Ojha A; Choe H; Farzan M
PLoS Pathog; 2021 Jan; 17(1):e1009212. PubMed ID: 33465165
[TBL] [Abstract][Full Text] [Related]
10. Reactive Centre Loop Mutagenesis of SerpinB3 to Target TMPRSS2 and Furin: Inhibition of SARS-CoV-2 Cell Entry and Replication.
Singh S; O'Reilly S; Gewaid H; Bowie AG; Gautier V; Worrall DM
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293378
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 Omicron entry is type II transmembrane serine protease-mediated in human airway and intestinal organoid models.
Mykytyn AZ; Breugem TI; Geurts MH; Beumer J; Schipper D; van Acker R; van den Doel PB; van Royen ME; Zhang J; Clevers H; Haagmans BL; Lamers MM
J Virol; 2023 Aug; 97(8):e0085123. PubMed ID: 37555660
[TBL] [Abstract][Full Text] [Related]
12. Dual Inhibition of Vacuolar-ATPase and TMPRSS2 Is Required for Complete Blockade of SARS-CoV-2 Entry into Cells.
Icho S; Rujas E; Muthuraman K; Tam J; Liang H; Landreth S; Liao M; Falzarano D; Julien JP; Melnyk RA
Antimicrob Agents Chemother; 2022 Jul; 66(7):e0043922. PubMed ID: 35703551
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 entry into human airway organoids is serine protease-mediated and facilitated by the multibasic cleavage site.
Mykytyn AZ; Breugem TI; Riesebosch S; Schipper D; van den Doel PB; Rottier RJ; Lamers MM; Haagmans BL
Elife; 2021 Jan; 10():. PubMed ID: 33393462
[TBL] [Abstract][Full Text] [Related]
14. Functional analysis of potential cleavage sites in the MERS-coronavirus spike protein.
Kleine-Weber H; Elzayat MT; Hoffmann M; Pöhlmann S
Sci Rep; 2018 Nov; 8(1):16597. PubMed ID: 30413791
[TBL] [Abstract][Full Text] [Related]
15. Middle East Respiratory Syndrome Coronavirus Spike Protein Is Not Activated Directly by Cellular Furin during Viral Entry into Target Cells.
Matsuyama S; Shirato K; Kawase M; Terada Y; Kawachi K; Fukushi S; Kamitani W
J Virol; 2018 Oct; 92(19):. PubMed ID: 30021905
[TBL] [Abstract][Full Text] [Related]
16. Identification of potent small molecule inhibitors of SARS-CoV-2 entry.
Mediouni S; Mou H; Otsuka Y; Jablonski JA; Adcock RS; Batra L; Chung DH; Rood C; de Vera IMS; Rahaim R; Ullah S; Yu X; Getmanenko YA; Kennedy NM; Wang C; Nguyen TT; Hull M; Chen E; Bannister TD; Baillargeon P; Scampavia L; Farzan M; Valente ST; Spicer TP
SLAS Discov; 2022 Jan; 27(1):8-19. PubMed ID: 35058179
[TBL] [Abstract][Full Text] [Related]
17. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
Li K; Meyerholz DK; Bartlett JA; McCray PB
mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553
[TBL] [Abstract][Full Text] [Related]
18. Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity.
Hoffmann M; Hofmann-Winkler H; Smith JC; Krüger N; Arora P; Sørensen LK; Søgaard OS; Hasselstrøm JB; Winkler M; Hempel T; Raich L; Olsson S; Danov O; Jonigk D; Yamazoe T; Yamatsuta K; Mizuno H; Ludwig S; Noé F; Kjolby M; Braun A; Sheltzer JM; Pöhlmann S
EBioMedicine; 2021 Mar; 65():103255. PubMed ID: 33676899
[TBL] [Abstract][Full Text] [Related]
19. An Updated Review on Betacoronavirus Viral Entry Inhibitors: Learning from Past Discoveries to Advance COVID-19 Drug Discovery.
Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA
Curr Top Med Chem; 2021; 21(7):571-596. PubMed ID: 33463470
[TBL] [Abstract][Full Text] [Related]
20. Highly Efficient SARS-CoV-2 Infection of Human Cardiomyocytes: Spike Protein-Mediated Cell Fusion and Its Inhibition.
Navaratnarajah CK; Pease DR; Halfmann PJ; Taye B; Barkhymer A; Howell KG; Charlesworth JE; Christensen TA; Kawaoka Y; Cattaneo R; Schneider JW;
J Virol; 2021 Nov; 95(24):e0136821. PubMed ID: 34613786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
